Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker Program
FUNDING OPPORTUNITY DESCRIPTION
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
Specifically, this RFP focuses on:
- Developing novel PET ligands for clinical trials
- Supporting novel CSF biomarkers
- Validating innovative MRI approaches in larger cohorts
- Developing novel measures of functional activity such as EEG
Peripheral biofluids and digital/ocular approaches are supported through the Diagnostics Accelerator RFP.
Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:
- Neuronal loss
- Vascular injury and blood-brain barrier integrity
- Mitochondria and metabolic function
- Protein misfolding
- Oxidative stress
- White matter changes
- Lewy body dementia
- Other novel targets supported by compelling biological rationale and connection to disease
The ADDF has limited interest in CSF measures of amyloid and tau.